MTOR and acquired polycythemia vera: Therefore, it is not surprising that the survival of PV was not more sensitive than AB to inhibitors of mTOR/PI-3K, including rapamycin a derivative of which, Everolimus, is under clinical investigation in MPN (53, 55, 57), predicting that treatments with PI-3K inhibitors alone may have limited efficacy in PV.